October 30, 2017 / 1:37 PM / a year ago

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

1 Min Read

Oct 30 (Reuters) - Newlink Genetics Corp

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

* ‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below